Management of Patients Who Develop Type 2 Diabetes While on Statin Therapy

Introduction to Statin Therapy in Diabetes

Patients who develop type 2 diabetes while on statin therapy for cardiovascular disease risk reduction should continue their statin therapy, as the cardiovascular benefits of statins significantly outweigh the diabetes risk, according to the American Diabetes Association 1

For patients aged 40-75 years with diabetes who develop additional cardiovascular risk factors, the American College of Cardiology recommends continuing high-intensity statin therapy (atorvastatin 40-80 mg daily) to reduce LDL-C by ≥50% from baseline 2, 3
For patients with established atherosclerotic cardiovascular disease (ASCVD), the American Heart Association recommends maintaining high-intensity statin therapy regardless of diabetes status, and considering adding non-statin LDL-lowering therapy (ezetimibe or PCSK9 inhibitor) if LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy 1, 2

The American Diabetes Association recommends assessing LDL-C levels 4-12 weeks after initiating therapy or changing doses to evaluate response, and emphasizing lifestyle modifications including dietary changes, weight management, and physical activity to help manage both diabetes and cardiovascular risk 2, 3, 4, 5

For combination therapy considerations, the American College of Cardiology recommends avoiding routine combination of statins with niacin due to lack of efficacy on major cardiovascular outcomes and possible increased risk of ischemic stroke, and exercising caution when combining statins with fibrates due to increased risk of myopathy 4, 5
The American Heart Association recommends not discontinuing statin therapy when diabetes develops, as this removes cardiovascular protection when it's most needed, and considering high-intensity statin therapy for diabetic patients with multiple cardiovascular risk factors 2